In the multivariate analysis that included the above eight factors as covariates, age at diagnosis (HR: 1.03, 95% CI: 1.00–1.06; p = 0.046), TET2 mutation (HR: 2.84, 95% CI: 1.26–6.36; p = 0.011), NLR (HR: 1.18, 95% CI: 1.06–1.32; p = 0.003) and history of remote thrombosis (HR: 5.33, 95% CI: 1.93–14.70; p = 0.001) remained risk factors for thrombosis in MPN patients (Table 2). This evidence concerns the gene TET2 and myeloproliferative neoplasm.